Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition

Abstract

The invention discloses a pharmaceutical composition for treating II-type diabetes and a preparation method of pharmaceutical composition. The pharmaceutical composition comprises the following ingredients in parts by weight: 80-150 parts of a crude fiber mixture, 60-90 parts of phycocyanobilin, 50-80 parts of patuletin, 38-76 parts of diosgenin, 35-70 parts of rutin, 16-30 parts of polyethylene glycol, 15-24 parts of pyridoxine, 12-18 parts of flavonoid glycosides, 10-16 parts of linoleic acid, 10-15 parts of sciadopitysin, 8-13 parts of kaempferol, 8-12 parts of quercetin, 7-11 parts of glutamic acid, 6-10 parts of lysine, 5-10 parts of tannin, 5-8 parts of flunarizine, 4-7 parts of thiamine and 2-6 parts of mixed enzyme. The pharmaceutical composition disclosed by the invention is a combination of traditional Chinese medicine and western medicines, effectively reduces the blood sugar and improves the glucose tolerance level of a muscle body on the basis of regulating the normal diet, regulates various abnormal indicators of the muscle body, enhances the tolerance of long-term drug use of a diabetic patient and reduces drug side effects. The pharmaceutical composition disclosed by the invention is simple in preparation process and convenient to use and has good clinical popularization significance.

Description

technical field [0001] The invention relates to the technical field of diabetes medication, in particular to a pharmaceutical composition for treating type II diabetes and a preparation method thereof. Background technique [0002] Diabetes is a common chronic metabolic disease characterized by hyperglycemia. It is caused by various pathogenic factors such as genetic factors, immune dysfunction, microbial infection and its toxins, free radical toxins, mental factors, etc. A series of metabolic disorder syndromes such as sugar, protein, fat, water and electrolytes caused by hypofunction and insulin resistance are one of the three most difficult diseases in the world. According to existing statistics, there are about 56 million people with diabetes in my country , and is growing at a rate of about 2 million per year. Diabetes has become the third largest non-communicable disease that endangers human health after cancer and cardiovascular disease. Therefore, it is particularly i...

AI Technical Summary

Problems solved by technology

[0003] At present, the clinical treatment of type Ⅱ diabetes is mainly oral western medicine, common ones are sulfonylureas, biguanides, α-glucosidase inhibitors, insulin sensitizers, glinide insulin secretagogues, etc. Long-term use can easily lead to Drug dependence and toxic side effects, and accelerate the aging of insulin cells, induce a variety of complications, so there is a need for a drug that can regulate eating habits to help reduce the impact of other multiple symptoms on blood sugar, and can control the patient's blood sugar It is one of the difficulties in developing type 2 diabetes mellitus medicines if it is kept within the normal range and is beneficial for long-term use without causing major harm to the body.